Targeting GRP receptor: Design, synthesis and preliminary biological characterization of new non-peptide antagonists of bombesin.
Antineoplastic Agents
/ chemical synthesis
Bombesin
/ analogs & derivatives
Cell Proliferation
/ drug effects
Dose-Response Relationship, Drug
Drug Design
Drug Screening Assays, Antitumor
Humans
Molecular Structure
Receptors, Bombesin
/ antagonists & inhibitors
Structure-Activity Relationship
Tumor Cells, Cultured
Bombesin (BN)
Circular dichroism
GRP receptors (GRP-R)
GRP-R antagonists
GRP-R ligands
Gastrin Releasing Peptide (GRP)
MM and MD conformational studies
NMR-based structural and conformational analysis
Journal
Bioorganic chemistry
ISSN: 1090-2120
Titre abrégé: Bioorg Chem
Pays: United States
ID NLM: 1303703
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
29
12
2020
revised:
03
02
2021
accepted:
04
02
2021
pubmed:
25
2
2021
medline:
1
10
2021
entrez:
24
2
2021
Statut:
ppublish
Résumé
We report the rational design, synthesis, and in vitro preliminary evaluation of a new small library of non-peptide ligands of Gastrin Releasing Peptide Receptor (GRP-R), able to antagonize its natural ligand bombesin (BN) in the nanomolar range of concentration. GRP-R is a transmembrane G-protein coupled receptor promoting the stimulation of cancer cell proliferation. Being overexpressed on the surface of different human cancer cell lines, GRP-R is ideal for the selective delivery to tumor cells of both anticancer drug and diagnostic devices. What makes very challenging the design of non-peptide BN analogues is that the 3D structure of the GRP-R is not available, which is the case for many membrane-bound receptors. Thus, the design of GRP-R ligands has to be based on the structure of its natural ligands, BN and GRP. We recently mapped the BN binding epitope by NMR and here we exploited the same spectroscopy, combined with MD, to define BN conformation in proximity of biological membranes, where the interaction with GRP-R takes place. The gained structural information was used to identify a rigid C-galactosidic scaffold able to support pharmacophore groups mimicking the BN key residues' side chains in a suitable manner for binding to GRP-R. Our BN antagonists represent hit compounds for the rational design and synthesis of new ligands and modulators of GRP-R. The further optimization of the pharmacophore groups will allow to increase the biological activity. Due to their favorable chemical properties and stability, they could be employed for the active receptor-mediated targeting of GRP-R positive tumors.
Identifiants
pubmed: 33626451
pii: S0045-2068(21)00116-4
doi: 10.1016/j.bioorg.2021.104739
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Receptors, Bombesin
0
Bombesin
PX9AZU7QPK
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
104739Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.